Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ORKA Oruka Therapeutics	$12.87 +2.1%	$10.06	$5.49 ▼ $31.13	$471.76M	-0.38	221,889 shs	138,587 shs
RAPP Rapport Therapeutics	$11.14 -7.9%	$10.47	$6.43 ▼ $29.74	$406.59M	N/A	171,181 shs	190,206 shs
RGNX REGENXBIO	$10.20	$8.37	$5.04 ▼ $15.36	$511.63M	1.09	924,508 shs	542,456 shs
THTX Theratechnologies	$2.53 -0.8%	$2.50	$1.12 ▼ $3.13	$117.25M	0.6	813,536 shs	66,958 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ORKA Oruka Therapeutics	-4.47%	+7.88%	+29.23%	+13.11%	+1,259,999,900.00%
RAPP Rapport Therapeutics	-8.05%	-7.35%	+15.57%	+20.76%	+1,209,999,900.00%
RGNX REGENXBIO	+3.98%	+1.19%	+27.98%	+55.73%	-24.89%
THTX Theratechnologies	-1.16%	-3.41%	-2.30%	+67.76%	+107.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ORKA Oruka Therapeutics	3.0744 of 5 stars	3.6	0.0	0.0	0.0	3.8	2.5	0.6
RAPP Rapport Therapeutics	1.7568 of 5 stars	3.5	0.0	0.0	0.0	2.3	1.7	0.6
RGNX REGENXBIO	4.2419 of 5 stars	3.4	2.0	0.0	4.6	1.9	3.3	0.6
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ORKA Oruka Therapeutics	3.20	Buy	$40.38	213.71% Upside
RAPP Rapport Therapeutics	3.00	Buy	$32.67	193.24% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	210.05% Upside
THTX Theratechnologies	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest THTX, RGNX, ORKA, and RAPP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
5/15/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/11/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$28.00
4/8/2025	RAPP Rapport Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	$156.72M	3.26	N/A	N/A	$7.09 per share	1.44
THTX Theratechnologies	$88.67M	1.31	N/A	N/A	($0.45) per share	-5.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ORKA Oruka Therapeutics	-$5.34M	-$4.51	N/A	N/A	N/A	N/A	-24.96%	-21.22%	7/30/2025 (Estimated)
RAPP Rapport Therapeutics	-$34.79M	-$3.45	N/A	N/A	N/A	N/A	N/A	N/A	8/14/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)
THTX Theratechnologies	-$23.96M	-$0.08	N/A	36.14	N/A	-3.75%	N/A	-4.31%	7/9/2025 (Estimated)

Latest THTX, RGNX, ORKA, and RAPP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	-$0.68	+$0.09	-$0.68	N/A	N/A
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ORKA Oruka Therapeutics	N/A	22.89	22.89
RAPP Rapport Therapeutics	N/A	45.91	45.91
RGNX REGENXBIO	N/A	3.05	3.05
THTX Theratechnologies	N/A	1.08	0.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ORKA Oruka Therapeutics	56.44%
RAPP Rapport Therapeutics	N/A
RGNX REGENXBIO	88.08%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
ORKA Oruka Therapeutics	24.69%
RAPP Rapport Therapeutics	N/A
RGNX REGENXBIO	12.79%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

THTX, RGNX, ORKA, and RAPP Headlines

Recent News About These Companies

Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

June 2, 2025 | marketbeat.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

Theratechnologies to further evaluate potential sale of the company

April 16, 2025 | markets.businessinsider.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | financialpost.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | globenewswire.com

Theratechnologies Engages in Exclusive Acquisition Talks

April 15, 2025 | tipranks.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | financialpost.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | businesswire.com

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

April 11, 2025 | globenewswire.com

Future Pak submits proposals to acquire Theratechnologies

April 11, 2025 | msn.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc. ...

April 11, 2025 | gurufocus.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

April 11, 2025 | businesswire.com

Theratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment Sours

April 9, 2025 | msn.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies receives FDA approval of PAS for EGRIFTA SV sBLA

April 8, 2025 | markets.businessinsider.com

3THTX : Examining the Future: Theratechnologies's Earnings Outlook

April 8, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, RGNX, ORKA, and RAPP Company Descriptions

Oruka Therapeutics NASDAQ:ORKA

$12.87 +0.27 (+2.14%)

As of 04:00 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Rapport Therapeutics NASDAQ:RAPP

$11.14 -0.96 (-7.93%)

As of 04:00 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

REGENXBIO NASDAQ:RGNX

$10.20 0.00 (0.00%)

As of 04:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Theratechnologies NASDAQ:THTX

$2.53 -0.02 (-0.78%)

As of 04:00 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time